ArticleViruses2026
Elicitation of Potent H5N1- and H7N9-Neutralizing Antibody Responses in Rhesus Macaques by Sequential Heterologous Vaccination with mRNA and Adenoviral Vectors Encoding Full-Length Hemagglutinins.
Brandon C Rosen, Jack T Mauter, Thomas B Voigt, Giovana de Figueiredo Godoy, Emma L Walker, Johan J Louw, Noor Ghosh, Christakis Panayiotou, Aaron Yrizarry-Medina, Joshua Terao and 6 more
Abstract read
In one paragraphArticle in Viruses, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registryThe trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literatureWho cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
4 · The recordCorrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what moneyAuthors and funding
16 authors.
Brandon C RosenDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.ORCID 0000-0002-4943-3494 Jack T MauterDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.ORCID 0009-0006-3192-3483 Thomas B VoigtDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.ORCID 0000-0003-2217-897X Giovana de Figueiredo GodoyDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.
Johan J LouwDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.
Noor GhoshDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.
Christakis PanayiotouDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.
Aaron Yrizarry-MedinaDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.
Joshua TeraoDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.
Eva G RakaszWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.ORCID 0000-0001-8197-5309 Matthew R ReynoldsWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.ORCID 0000-0002-1484-6408 Dawn M DudleyWisconsin National Primate Research Center, University of Wisconsin-Madison, Madison, WI 53715, USA.
David I WatkinsDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.
Michael J RicciardiDepartment of Pathology, George Washington University School of Medicine and Health Sciences, Washington, DC 20052, USA.ORCID 0000-0002-8098-8666 Funding
WNPRC Supplemental Request for Nonhuman Primate Enclosures to Equip HIV/AIDS-Related Research FacilitiesP51OD011106 · OD · UNIVERSITY OF WISCONSIN-MADISON · PI Dorota A. Grejner-Brzezinska · 2012 to 2026
$150.7MPractices CoreUC7AI180311 · NIAID · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI William Paul Duprex · 2023 to 2026
$13.2MLearning from the Ebola success: Can a mAb also save lives after yellow fever infection?R42AI155275 · NIAID · MABLOC, LLC · PI WATKINS, DAVID I · 2020 to 2023
$3.3MNIAID NIH HHS R42 AI155275NIAID NIH HHS UC7 AI180311NIH HHS 5P51OD11106-64NIH HHS 5R42AI155275-04NIH HHS 5UC7AI180311-03NIH HHS P51 OD011106
6 · The paper itselfAbstract
Highly pathogenic avian influenza (HPAI) represents an enormous pandemic risk amid the ongoing H5N1 panzootic. HPAI, defined by its high lethality in domestic poultry, includes the influenza A virus (IAV) H5N1 and H7N9 subtypes and has a 40-50% case fatality rate in humans. To facilitate the development of efficacious HPAI vaccination regimens and isolation of HPAI-neutralizing monoclonal antibodies (nmAbs) for prophylactic and therapeutic use, we performed a proof-of-concept pilot study wherein we developed an array of mRNA and adenovirus-vectored vaccines encoding HPAI hemagglutinins (HAs) and then assessed their immunogenicity in IAV-naïve Indian rhesus macaques (RMs). All RMs developed binding IgG recognizing both HPAI HAs. HPAI-nAbs were detected in RMs vaccinated with full-length HAs, but not in RMs vaccinated with HA stems alone. Potent HPAI neutralization activity was observed in two animals with serum ID
Indexed as
Antibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusInfluenza A Virus, H5N1 SubtypeInfluenza A Virus, H7N9 SubtypeInfluenza VaccinesAdenoviridaeAnimalsGenetic VectorsImmunoglobulin GMacaca mulattaOrthomyxoviridae InfectionsPilot ProjectsRNA, MessengerVaccinationAntibodies, NeutralizingAntibodies, ViralHemagglutinin Glycoproteins, Influenza VirusImmunoglobulin GInfluenza VaccinesRNA, MessengerantibodiesB lymphocytesH5N1H7N9highly pathogenic avian influenzainfluenza A virusvaccines
Identifiers
PMID42797812
PMCPMC13611895
What OpenQuestion holds
Textmetadata
Read underepoch 390